Physician profile
Randall Cron
NPI 1053331561
$55,607.25
in general payments reported to CMS, 2019-2025
17 companies · $6,938 in 2025
The $6,938 reported for 2025 was more than what 93% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,045 · 2021: $6,724 · 2022: $1,099 · 2023: $1,817 · 2024: $24K · 2025: $6,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $8,985 · Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,908.54 |
| Travel and Lodging | $8,985.07 |
| Food and Beverage | $1,283.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20,955.34 | 2019-2025 | |
| Swedish Orphan Biovitrum Ab | $12,585.07 | 2024 | |
| Novartis Pharmaceuticals Corporation | $8,053.93 | 2019-2021 | |
| Pfizer INC. | $7,007.50 | 2019-2025 | |
| Abbvie INC. | $4,514.79 | 2019-2024 | Rinvoq |
| Amgen INC. | $542.27 | 2019-2025 | Tavneos |
| Glaxosmithkline, LLC. | $365.23 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $314.38 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $258.85 | 2025 | Lupkynis |
| Ucb, INC. | $250.00 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $247.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $130.77 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2019 | |
| Genentech USA, INC. | $115.71 | 2019 | |
| Genzyme Corporation | $111.83 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $16.82 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Cron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.